Transplant Infectious Disease · 2010 · 13 citations · 5 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacotherapyTransplant ImmunologyTransplant PharmacotherapyHematopoietic Stem Cell Transplant PharmacotherapyImmunosuppressionTransplant PharmacologyAcquired Immunodeficiency SyndromeAllogeneic Stem Cell TherapyAllogeneic Transplant PharmacotherapyImmunosuppressive Drug TherapyTrimethoprim-sulfamethoxazole Therapy
P.J. Kiel, N. Dickmeyer, J.E. Schwartz. Trimethoprim–sulfamethoxazole-induced rhabdomyolysis in an allogeneic stem cell transplant patient.Transpl Infect Dis 2010: 12: 451–454. All rights reserved Abstract: Rhabdomyolysis is a serious, potentially life-threatening complication diagnosed when creatine phosphokinase levels exceed 1000 U/L. Although many drugs are associated with rhabdomyolysis, the previous reports of trimethoprim–sulfamethoxazole (TMP/SMX)-induced rhabdomyolysis have involved patients with human immunodeficiency virus/acquired immunodeficiency syndrome. This is the first report, to our knowledge, of TMP/SMX-induced rhabdomyolysis in an allogeneic stem cell transplant patient.
5
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations